ERBB2 and cholangiocarcinoma: We have provided an excellent preclinical evaluation of the efficacy of a lapatinib-gemcitabine combination-based therapy which can be applied to future treatments of HER2-overexpressed cholangiocarcinoma, while simultaneously shedding new light on the potential of molecular targeted CCA therapies.